Please login to the form below

Not currently logged in
Email:
Password:

Abeona Therapeutics names CEO

Carsten Thiel joins the biopharma from Alexion

Rare genetic disease focused biopharma Abeona Therapeutics has named its chief executive officer in the form of Carsten Thiel.

Formerly serving as Alexion Pharmaceutical’s executive vice president and chief commercial officer, Thiel brings experience in leading commercial operations to his new position.

Steven Rouhandeh, executive chairman of Abeona, said: “As CEO, Carsten Thiel brings a unique combination of extensive experience in research and global rare disease commercialisation to Abeona.

“In his recent positions, he successfully created value by building cohesive talented teams, driving the commercial success of multiple products globally and fostering entrepreneurial culture; all key aspects that will be critical to our success in these areas in the years ahead.”

Following a 25-year career in the biopharmaceutical industry, Thiel has held numerous roles for several biopharma’s including Amgen and Roche.

20th April 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Dimitri Azzopardi
Case-study for thalassaemia: Dimitri Azzopardi
An in-depth look at beta thalassaemia for Rare Disease Day...
Delivering change through better rare disease communications
OPEN Health’s Richard Jones, Gemma Allen and Charlotte Richards discuss how pharma can utilise tools, channels and stakeholders to deliver change and enable better outcomes....
Interim analysis clinical trials
Assessing the value of interim analyses in clinical trials
Why its important and when its needed...

Infographics